Damora Therapeutics Opens Mutant-CALR Trial

Company: Damora Therapeutics · Event Type: Pivotal Trial Initiation (Phase 1/1b) · Modality: Fc-Null Monoclonal Antibody · Asset: DMR-001 · Indication: Mutant-CALR Essential Thrombocythemia / Myelofibrosis Summary Damora Therapeutics initiated CLARITY-101, a global Phase 1/1b trial of DMR-001 in adults with mutant-calreticulin-driven essential thrombocythemia or…